GSK vs XELB · P/E 13, $103.31B cap vs rev $2.3M
GlaxoSmithKline PLC ADR (GSK) versus Xcel Brands Inc (XELB) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Xcel Brands Inc (XELB) is a apparel manufacturing company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported XELB revenue for 2026-06-30 was $2.3M. Net income was -$5.0M. Revenue was up 98.0% from 2026-03-31 to 2026-06-30. XELB currently screens at market cap $7.4M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. XELB currently screens at market cap $7.4M.
Not investment advice. Open the GSK and XELB stock pages for the full models.
Not investment advice.